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fiAt 40 years of age, American men and women have
a 1 in 5 lifetime risk of the development of heart
failure (HF); by the latest estimates, there are
5,700,000 people in the United States who already
have a diagnosis of the disease. Moreover, by the
year 2030, it is predicted that an additional 3
million Americans will have HF, representing an
astounding 25% increase from 2010. Many of these
individuals will be older than 65 years of age (1).
Clearly, there is an urgent need to identify patients
at risk of the development of HF and to initiate
effective preventive measures.
See page 874
What can be done to prevent HF and the
resulting personal and societal costs? A first step
toward recognizing the importance of risk factors
leading to HF came with a shift in classification of
HF. Instead of focusing solely on the time-honored
New York Heart Association functional classifica-
tion scheme—a useful method to quantify the
degree of functional limitation of the patient with
established HF—the American Heart Association
(AHA) and American College of Cardiology
(ACC) endorsed the use of a staging system focused
on both pathophysiology and symptoms (2). The
staging system and recommended treatment ac-
cording to stage are presented in Figure 1 (3).
Notably, 2 of the 4 categories, stages A and B,
identify patients who are asymptomatic, in an effort
to emphasize the need to intervene with proven
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contents of this paper to disclose.herapies even before patients become symptomatic
ith more advanced stages of HF. Stage A repre-
ents patients with risk factors for HF, including
raditional risk factors for coronary artery disease
CAD) and CAD itself. Stage B represents patients
ith structural heart disease, including left ventric-
lar hypertrophy or systolic dysfunction, but who
emain without HF symptoms. It is still a matter of
ebate whether asymptomatic diastolic dysfunction
s stage A or B. In any case, according to a
ommunity-based cohort in Olmsted County, Min-
esota,56% of adults older than 45 years of age were
lassified as stage A (22%) or B (34%). Thus, HF was
ikely to develop in at least half of this randomly
elected Olmsted County population and could be
dentified before the onset of HF symptoms by med-
cal record abstraction, physical examination, self-
dministered Goldman SAS questionnaire, echocar-
iography, and electrocardiography (4).
In this issue of iJACC, Leening et al. (5) suggest
n important additional component of the algo-
ithm to predict HF by adding to what is already
nown about the relationship between coronary
rtery calcium (CAC) and HF (6,7). In their
rospective, cohort study of 1,897 asymptomatic
utch subjects older than 55 years of age, the
uthors found a graded association between the
xtent of CAC, as measured by electron-beam
omputed tomography, and the risk of incident HF,
ver a follow-up period of almost 7 years. Remark-
bly, when corrected for age, sex, and standard car-
iovascular risk factors and censoring subjects with
ncident nonfatal coronary heart disease, a 3-fold
ncreased risk of HF remained, suggesting an associ-
tion between CAC and HF separate from overt
oronary disease in this population (5). Importantly,
he Rotterdam cohort was older, so that this study’s
ndings should not be generalized to a younger
opulation or necessarily to one that is more racially
HF  heart failure; LV ial i
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882diverse, such as the U.S. population, until it is repli-
cated in another source population. We know from
previous studies, for example, that differences in CAC
exist among ethnic groups (8), although these differ-
ences remain poorly understood.
Nonetheless, subjects with increased CAC can be
considered to have at least ACC/AHA stage A
disease and should be targeted with aggressive
strategies to prevent progression to symptomatic
disease. One could argue that, on the basis of recent
work looking at regional myocardial dysfunction
found in asymptomatic subjects, in some of whom
HF does develop (9), and the correlation found
between areas of CAC and areas of wall motion
dysfunction seen on cardiac magnetic resonance
imaging (10), these subjects may in fact have subtle
structural dysfunction, thereby classifying patients
with high CAC scores as ACC/AHA stage B.
Regrettably, the Leening et al. (5) study was unable
to capture whether HF developed in subjects with
reduced or preserved ejection fraction, which may
play a role in the pathophysiology of the subsequent
development of HF. In future studies, it would be
useful to have this distinction. Most importantly, it
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883The larger question to be answered in future
studies is how do we lessen this risk, above and
beyond treatment of standard cardiovascular risk
factors? Will our interventions depend on the type
of HF (systolic or diastolic) that is involved? Similar
to the emerging story with biomarkers, where
natriuretic peptides have shown incremental value
in predicting the risk of incident HF (17), we needCirculation 2007;115:1563–70.
1
1
1
Effect of obesity aproven methods to mitigate the hazard, with a
widespread application of prevention measures to
our diverse U.S. population.
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